Warfarin: a case history in pharmacogenetics

被引：14

作者：

Hall, AM ^{[1
]}

Wilkins, MR ^{[1
]}

机构：

[1] Univ London Imperial Coll Sci & Technol, Hammersmith Hosp, London W12 0NN, England

来源：

HEART | 2005年 / 91卷 / 05期

关键词：

D O I：

10.1136/hrt.2004.051771

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Both hereditary and environmental factors contribute to inter-individual variability in drug response. The considerable interest in the role of genes has to be balanced with the contribution of external influences. Warfarin provides a useful case study of the need to integrate both genetic and non-genetic information when selecting the right dose for a patient. This article discusses the latest data on genotype and warfarin sensitivity and the efforts to incorporate this information into normograms. Exploring the genetics of warfarin response will lead not only to safer prescribing but elucidate the mechanism of action of warfarin and enable the development of new anticoagulant drugs.

引用

页码：563 / 564

页数：2

共 20 条

[1] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].

Aithal, GP ;

Day, CP ;

Kesteven, PJL ;

Daly, AK .

LANCET, 1999, 353 (9154) :717-719

[2] Testing drug response in the presence of genetic information: sampling issues for clinical trials [J].

Cardon, LR ;

Idury, RM ;

Harris, TJR ;

Witte, JS ;

Elston, RC .

PHARMACOGENETICS, 2000, 10 (06) :503-510

[3]

DANDREA G, 2004, BLOOD 0909

[4] Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy [J].

Douketis, JD ;

Foster, GA ;

Crowther, MA ;

Prins, MH ;

Ginsberg, JS .

ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (22) :3431-3436

[5] Pharmacogenetics and anticoagulant therapy [J].

Gage, BF ;

Eby, CS .

JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2003, 16 (1-2) :73-78

[6] Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin [J].

Gage, BF ;

Eby, C ;

Milligan, PE ;

Banet, GA ;

Duncan, JR ;

McLeod, HL .

THROMBOSIS AND HAEMOSTASIS, 2004, 91 (01) :87-94

[7] Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms [J].

Haining, RL ;

Hunter, AP ;

Veronese, ME ;

Trager, WF ;

Rettie, AE .

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1996, 333 (02) :447-458

[8] Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy [J].

Higashi, MK ;

Veenstra, DL ;

Kondo, LML ;

Wittkowsky, AK ;

Srinouanprachanh, SL ;

Farin, FM ;

Rettie, AE .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13) :1690-1698

[9] Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype [J].

Hillman, MA ;

Wilke, RA ;

Caldwell, MD ;

Berg, RL ;

Glurich, I ;

Burmester, JK .

PHARMACOGENETICS, 2004, 14 (08) :539-547

[10] American Heart Association American College of Cardiology - Foundation guide to warfarin therapy [J].

Hirsh, J ;

Fuster, V ;

Ansell, J ;

Halperin, JL .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (09) :1633-1652

← 1 2 →